Skip to content
Homepage
Author:
Synklino
Posted Date:
May 28, 2026
Synklino announces first patient dosed in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation
Synklino
May 28, 2026
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
Synklino
February 25, 2026
